Scotland-based biomaterials firm Biogelx has announced the appointment of a new CEO, Alison Clayton. Clayton will take over the leading position from Mitch Scanlan, who recently retired. The company has also announced the appointment of Margaret Temple to its board of directors as well as the completion of a successful round of fundraising.
Clayton has over 25 years of experience working in the contract testing industry, working for companies including Eurofins, Quintiles and Aptuit. The new Biogelx CEO also holds a degree and PhD in Pharmacology from the University of Glasgow and spent seven years conducting research in several post-doctoral positions. Clayton will bring this varied experience to Biogelx, a company that specializes in the production of synthetic bioprinting materials.
“We are absolutely delighted to have Alison come on board here at Biogelx,” said John Waddell, the company’s Chairman. “Her commercial experience coupled with her academic background will help move the company to the next phase of its evolution.”
“I am excited to be joining Biogelx at this time when the applications for the products in 3D Bioprinting and also 3D Cell Culture are growing.” added Clayton. “We have extensive collaborations ongoing with both academia and commercial organisations which further develop the applications for the products maximising their utility within the research and development space.”
In addition to the appointment of a new CEO, Biogelx has also welcomed Margaret Temple to its board of directors as non-executive director. Temple has worked in the life sciences industry for over two decades and has over 25 years of experience in the life science CRO sector. In 2007, she co-founded biopharmaceutical company Vitrology Ltd. and served as CEO until it was acquired by Swiss multinational SGS in 2012.
To round off its new appointments, Biogelx has also revealed it has closed a successful round of financing, the funding from which will enable it to continue its growth and the development of new hydrogel and bioink products for bioprinting and 3D cell culture. The funding round saw participation from the University of Strathclyde, the Scottish Investment Bank and their private investors.